Beneficial Effects of the Activation of the Angiotensin-(1-7) Mas Receptor in a Murine Model of Adriamycin-Induced Nephropathy

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Da Silveira, Kátianiela ^a   Barroso, Lívia Corrêa ^a   Vieira, Angélica Thomáz ^a   Cisalpino, Daniel ^a   Lima, Cristiano Xavier ^a   Bader, Michael ^b   Arantes, Rosa Maria Esteves ^a   dos Santos, Robson Augusto Souza ^a   Simões e Silva, Ana Cristina ^a   Teixeira, Mauro Martins ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1A RECEPTOR; ANGIOTENSIN[1-7]; CREATININE; DOXORUBICIN; LOSARTAN; MESSENGER RNA; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; ENZYME ACTIVATION; HISTOPATHOLOGY; KIDNEY DISEASE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

ANGIOTENSIN I; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; DISEASE MODELS, ANIMAL; DOXORUBICIN; GENE EXPRESSION REGULATION; HUMANS; IMIDAZOLES; KIDNEY DISEASES; KIDNEY GLOMERULUS; KIDNEY TUBULES; LOSARTAN; MICE; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER; TIME FACTORS;

MURINAE; MUS;

EID: 84878804366     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066082     Document Type: Article

References (58)

1. Benter IF, Ferrario CM, Morris M, Diz DI, (1995) Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol 269: H313-319.
2. Santos RA, Ferreira AJ, Simoes e Silva AC, (2008) Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol 93: 519-527.
3. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, et al. (2005) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366: 2026-2033.
4. Ji Z, Huang C, Liang C, Chen B, Chen S, et al. (2005) Protective effects of blocking renin-angiotensin system on the progression of renal injury in glomerulosclerosis. Cell Mol Immunol 2: 150-154.
5. Mihailovic-Stanojevic N, Jovovic D, Miloradovic Z, Grujic-Milanovic J, Jerkic M, et al. (2009) Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan. Nephrol Dial Transplant 24: 1142-1150.
6. Ruilope LM, (2008) Angiotensin receptor blockers: RAAS blockade and renoprotection. Curr Med Res Opin 24: 1285-1293.
7. Pinheiro SV, Simoes e Silva AC, Sampaio WO, de Paula RD, Mendes EP, et al. (2004) Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension 44: 490-496.
8. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100: 8258-8263.
9. Botelho-Santos GA, Sampaio WO, Reudelhuber TL, Bader M, Campagnole-Santos MJ, et al. (2007) Expression of an angiotensin-(1-7)-producing fusion protein in rats induced marked changes in regional vascular resistance. Am J Physiol Heart Circ Physiol 292: H2485-2490.
10. Magaldi AJ, Cesar KR, de Araujo M, Simoes e Silva AC, Santos RA, (2003) Angiotensin-(1-7) stimulates water transport in rat inner medullary collecting duct: evidence for involvement of vasopressin V2 receptors. Pflugers Arch 447: 223-230.
11. Lara LS, Vives D, Correa JS, Cardozo FP, Marques-Fernades MF, et al. (2010) PKA-mediated effect of MAS receptor in counteracting angiotensin II-stimulated renal Na+-ATPase. Arch Biochem Biophys 496: 117-122.
12. Giani JF, Munoz MC, Pons RA, Cao G, Toblli JE, et al. (2011) Angiotensin-(1-7) reduces proteinuria and diminishes structural damage in renal tissue of stroke-prone spontaneously hypertensive rats. Am J Physiol Renal Physiol 300: F272-282.
13. Dhaunsi GS, Yousif MH, Akhtar S, Chappell MC, Diz DI, et al. Angiotensin-(1-7) prevents diabetes-induced attenuation in PPAR-gamma and catalase activities. Eur J Pharmacol 638: 108-114.
14. Benter IF, Yousif MH, Dhaunsi GS, Kaur J, Chappell MC, et al. (2008) Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol 28: 25-33.
15. Silveira KD, Coelho FM, Vieia AT, Sachs D, Barroso LC, et al. (2010) Anti-inflammatory effects of the activation of the Angiotensin-(1-7) receptor, Mas, in experimental models of arthritis. The Journal of Immunology 185 (9) (): 5569-76.
16. Pinheiro SV, Ferreira AJ, Kitten GT, da Silveira KD, da Silva DA, et al. (2009) Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. Kidney Int 75: 1184-1193.
17. Esteban V, Heringer-Walther S, Sterner-Kock A, de Bruin R, van den Engel S, et al. (2009) Angiotensin-(1-7) and the g protein-coupled receptor MAS are key players in renal inflammation. PLoS One 4: e5406.
18. Chen A, Sheu LF, Ho YS, Lin YF, Chou WY, et al. (1998) Experimental focal segmental glomerulosclerosis in mice. Nephron 78: 440-452.
19. Wang Y, Wang YP, Tay YC, Harris DC, (2000) Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int 58: 1797-1804.
20. Krege JH, Hodgin JB, Hagaman JR, Smithies O, (1995) A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25: 1111-1115.
21. Lan HY, Nikolic-Paterson DJ, Mu W, Atkins RC, (1995) Local macrophage proliferation in the progression of glomerular and tubulointerstitial injury in rat anti-GBM glomerulonephritis. Kidney Int 48: 753-760.
22. Tsakas S, Goumenos DS, (2006) Accurate measurement and clinical significance of urinary transforming growth factor-beta1. Am J Nephrol 26: 186-193.
23. Lee VW, Harris DC, (2011) Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrology (Carlton) 16: 30-38.
24. Bertani T, Poggi A, Pozzoni R, Delaini F, Sacchi G, et al. (1982) Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab Invest 46: 16-23.
25. Dilauro M, Burns KD, (2009) Angiotensin-(1-7) and its effects in the kidney. ScientificWorldJournal 9: 522-535.
26. van der Wouden EA, Henning RH, Deelman LE, Roks AJ, Boomsma F, et al. (2005) Does angiotensin (1-7) contribute to the anti-proteinuric effect of ACE-inhibitors. J Renin Angiotensin Aldosterone Syst 6: 96-101.
27. Zhang J, Noble NA, Border WA, Huang Y, (2010) Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. Am J Physiol Renal Physiol 298: F579-588.
28. Velkoska E, Dean RG, Griggs K, Burchill L, Burrell LM, (2011) Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. Clin Sci (Lond) 120: 335-345.
29. Chappell MC, Modrall JG, Diz DI, Ferrario CM, (2004) Novel aspects of the renal renin-angiotensin system: angiotensin-(1-7), ACE2 and blood pressure regulation. Contrib Nephrol 143: 77-89.
30. Silveira KD, Pompermayer Bosco KS, Diniz LR, Carmona AK, Cassali GD, et al. (2010) ACE2-angiotensin-(1-7)-Mas axis in renal ischaemia/reperfusion injury in rats. Clin Sci (Lond) 119: 385-394.
31. Barroso LC, Silveira KD, Lima CX, Borges V, Bader M, et al. (2012) Renoprotective Effects of AVE0991, a Nonpeptide Mas Receptor Agonist, in Experimental Acute Renal Injury. Int J Hypertens 2012: 808726.
32. Silveira KD, Santos RAS, Barroso LC, Lima CX, Teixeira MM, et al. (2010) The administration of the agonist of angiotensin-(1-7), AVE0991, improved inflammation and proteinuria in experimental nephrotic syndrome. In:15th Congress of the International Pediatric Nephrology Association. Pediatric Nephrology 25: 1779-2004.
33. Matsusaka T, Asano T, Niimura F, Kinomura M, Shimizu A, et al. (2010) Angiotensin receptor blocker protection against podocyte-induced sclerosis is podocyte angiotensin II type 1 receptor-independent. Hypertension 55: 967-973.
34. Naito T, Ma LJ, Yang H, Zuo Y, Tang Y, et al. (2010) Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. Am J Physiol Renal Physiol 298: F683-691.
35. Shimizu A, Zhong J, Miyazaki Y, Hosoya T, Ichikawa I, et al. (2012) ARB protects podocytes from HIV-1 nephropathy independently of podocyte AT1. Nephrol Dial Transplant 27: 3169-3175.
36. Border WA, Noble NA, (1998) Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 31: 181-188.
37. Sun Y, Zhang J, Zhang JQ, Ramires FJ, (2000) Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension 35: 1078-1084.
38. Kagami S, Border WA, Miller DE, Noble NA, (1994) Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93: 2431-2437.
39. Crowley SD, Vasievich MP, Ruiz P, Gould SK, Parsons KK, et al. (2009) Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest 119: 943-953.
40. He JG, Chen SL, Huang YY, Chen YL, Dong YG, et al. The nonpeptide AVE0991 attenuates myocardial hypertrophy as induced by angiotensin II through downregulation of transforming growth factor-beta1/Smad2 expression. Heart Vessels 25: 438-443.
41. Li Y, Wu J, He Q, Shou Z, Zhang P, et al. (2009) Angiotensin (1-7) prevent heart dysfunction and left ventricular remodeling caused by renal dysfunction in 5/6 nephrectomy mice. Hypertens Res 32: 369-374.
42. Su Z, Zimpelmann J, Burns KD, (2006) Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int 69: 2212-2218.
43. Gava E, Samad-Zadeh A, Zimpelmann J, Bahramifarid N, Kitten GT, et al. (2009) Angiotensin-(1-7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells. Nephrol Dial Transplant 24: 1766-1773.
44. Zimpelmann J, Burns KD, (2009) Angiotensin-(1-7) activates growth-stimulatory pathways in human mesangial cells. Am J Physiol Renal Physiol 296: F337-346.
45. Shao Y, He M, Zhou L, Yao T, Huang Y, et al. (2008) Chronic angiotensin (1-7) injection accelerates STZ-induced diabetic renal injury. Acta Pharmacol Sin 29: 829-837.
46. Santos RA, Castro CH, Gava E, Pinheiro SV, Almeida AP, et al. (2006) Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension 47: 996-1002.
47. Pereira RM, Dos Santos RA, Teixeira MM, Leite VH, Costa LP, et al. (2007) The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1-7). J Hepatol 46: 674-681.
48. Okada H, Watanabe Y, Inoue T, Kobayashi T, Kikuta T, et al. (2004) Angiotensin II type 1 receptor blockade attenuates renal fibrogenesis in an immune-mediated nephritic kidney through counter-activation of angiotensin II type 2 receptor. Biochem Biophys Res Commun 314: 403-408.
49. Satoh M, Kashihara N, Yamasaki Y, Maruyama K, Okamoto K, et al. (2001) Renal interstitial fibrosis is reduced in angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 12: 317-325.
50. Averill DB, Ishiyama Y, Chappell MC, Ferrario CM, (2003) Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation 108: 2141-2146.
51. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, et al. (2004) Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43: 970-976.
52. Katovich MJ, Grobe JL, Raizada MK, (2008) Angiotensin-(1-7) as an antihypertensive, antifibrotic target. Curr Hypertens Rep 10: 227-232.
53. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, et al. (2005) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111: 2605-2610.
54. Ferrario CM, Jessup J, Gallagher PE, Averill DB, Brosnihan KB, et al. (2005) Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 68: 2189-2196.
55. Igase M, Yokoyama H, Ferrario CM, (2011) Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1-7). Ther Adv Cardiovasc Dis 5: 297-304.
56. Sukumaran V, Veeraveedu PT, Gurusamy N, Lakshmanan AP, Yamaguchi K, et al. (2012) Telmisartan acts through the modulation of ACE-2/ANG 1-7/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis. Life Sci 90: 289-300.
57. Sukumaran V, Veeraveedu PT, Gurusamy N, Yamaguchi K, Lakshmanan AP, et al. (2011) Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis. Int J Biol Sci 7: 1077-1092.
58. Zong WN, Yang XH, Chen XM, Huang HJ, Zheng HJ, et al. (2011) Regulation of angiotensin-(1-7) and angiotensin II type 1 receptor by telmisartan and losartan in adriamycin-induced rat heart failure. Acta Pharmacol Sin 32: 1345-1350.